JP4276945B2 - α−Ｄ−ガラクトシダーゼ活性が低下したコーヒー植物 - Google Patents
α−Ｄ−ガラクトシダーゼ活性が低下したコーヒー植物 Download PDFInfo
- Publication number
- JP4276945B2 JP4276945B2 JP2003535528A JP2003535528A JP4276945B2 JP 4276945 B2 JP4276945 B2 JP 4276945B2 JP 2003535528 A JP2003535528 A JP 2003535528A JP 2003535528 A JP2003535528 A JP 2003535528A JP 4276945 B2 JP4276945 B2 JP 4276945B2
- Authority
- JP
- Japan
- Prior art keywords
- coffee
- galactosidase
- plant
- sequence
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108010030291 alpha-Galactosidase Proteins 0.000 title claims abstract description 58
- 102000005840 alpha-Galactosidase Human genes 0.000 title claims abstract description 50
- 230000000694 effects Effects 0.000 title claims abstract description 29
- 240000007154 Coffea arabica Species 0.000 title claims description 42
- 241000196324 Embryophyta Species 0.000 claims abstract description 27
- 241000533293 Sesbania emerus Species 0.000 claims abstract description 13
- 235000013353 coffee beverage Nutrition 0.000 claims description 24
- 150000007523 nucleic acids Chemical class 0.000 claims description 13
- 229930182830 galactose Natural products 0.000 claims description 9
- 108020005544 Antisense RNA Proteins 0.000 claims description 8
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 8
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 230000001965 increasing effect Effects 0.000 claims description 6
- 235000021539 instant coffee Nutrition 0.000 claims description 6
- 101150064416 csp1 gene Proteins 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- 229920002477 rna polymer Polymers 0.000 claims description 4
- 230000009261 transgenic effect Effects 0.000 claims description 4
- 230000007423 decrease Effects 0.000 claims description 3
- 230000001973 epigenetic effect Effects 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 claims 1
- 102000048120 Galactokinases Human genes 0.000 claims 1
- 108700023157 Galactokinases Proteins 0.000 claims 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims 1
- 108700026220 vif Genes Proteins 0.000 claims 1
- 229920000926 Galactomannan Polymers 0.000 abstract description 10
- 238000012986 modification Methods 0.000 abstract description 2
- 230000004048 modification Effects 0.000 abstract description 2
- 239000013598 vector Substances 0.000 description 33
- 239000002299 complementary DNA Substances 0.000 description 20
- 230000000692 anti-sense effect Effects 0.000 description 15
- 108020004999 messenger RNA Proteins 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 11
- 210000002257 embryonic structure Anatomy 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 239000002773 nucleotide Substances 0.000 description 10
- 125000003729 nucleotide group Chemical group 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 230000000392 somatic effect Effects 0.000 description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 230000009466 transformation Effects 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 6
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 229920000057 Mannan Polymers 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000035800 maturation Effects 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000007993 MOPS buffer Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 239000006870 ms-medium Substances 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- IFBHRQDFSNCLOZ-IIRVCBMXSA-N 4-nitrophenyl-α-d-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC1=CC=C([N+]([O-])=O)C=C1 IFBHRQDFSNCLOZ-IIRVCBMXSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010020649 Hyperkeratosis Diseases 0.000 description 3
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 description 3
- 229960004261 cefotaxime Drugs 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 101100352418 Caenorhabditis elegans plp-1 gene Proteins 0.000 description 2
- 241000769888 Canephora <angiosperm> Species 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 101100437498 Escherichia coli (strain K12) uidA gene Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004345 fruit ripening Effects 0.000 description 2
- -1 galactomannan polysaccharides Chemical class 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000031787 nutrient reservoir activity Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000005070 ripening Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 239000005496 Chlorsulfuron Substances 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000723377 Coffea Species 0.000 description 1
- 235000007460 Coffea arabica Nutrition 0.000 description 1
- 244000016593 Coffea robusta Species 0.000 description 1
- 235000002187 Coffea robusta Nutrition 0.000 description 1
- 241000032203 Conus aureus Species 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 101150064744 Hspb8 gene Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 241000220641 Isoleucas arabica Species 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 240000002769 Morchella esculenta Species 0.000 description 1
- 235000002779 Morchella esculenta Nutrition 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 101710199392 TATA-box-binding protein 1 Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 229940107050 alpha-d-galactosidase enzyme Drugs 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- VJYIFXVZLXQVHO-UHFFFAOYSA-N chlorsulfuron Chemical compound COC1=NC(C)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)Cl)=N1 VJYIFXVZLXQVHO-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000008722 morphological abnormality Effects 0.000 description 1
- 125000006501 nitrophenyl group Chemical group 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 239000012882 rooting medium Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 101150075348 sta gene Proteins 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- WCTAGTRAWPDFQO-UHFFFAOYSA-K trisodium;hydrogen carbonate;carbonate Chemical compound [Na+].[Na+].[Na+].OC([O-])=O.[O-]C([O-])=O WCTAGTRAWPDFQO-UHFFFAOYSA-K 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
- C12N15/8245—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine involving modified carbohydrate or sugar alcohol metabolism, e.g. starch biosynthesis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Tea And Coffee (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01124160 | 2001-10-10 | ||
| PCT/EP2002/009148 WO2003032713A2 (en) | 2001-10-10 | 2002-08-15 | COFFEE PLANT WITH REDUCED α-D-GALACTOSIDASE ACTIVITY |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005505290A JP2005505290A (ja) | 2005-02-24 |
| JP2005505290A5 JP2005505290A5 (enExample) | 2009-03-05 |
| JP4276945B2 true JP4276945B2 (ja) | 2009-06-10 |
Family
ID=8178911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003535528A Expired - Fee Related JP4276945B2 (ja) | 2001-10-10 | 2002-08-15 | α−Ｄ−ガラクトシダーゼ活性が低下したコーヒー植物 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7238858B2 (enExample) |
| EP (1) | EP1436402B1 (enExample) |
| JP (1) | JP4276945B2 (enExample) |
| CN (1) | CN1635895A (enExample) |
| AT (1) | ATE318319T1 (enExample) |
| AU (1) | AU2002333434B2 (enExample) |
| BR (1) | BR0213180A (enExample) |
| CA (1) | CA2457821A1 (enExample) |
| CO (1) | CO5580845A2 (enExample) |
| DE (1) | DE60209380T2 (enExample) |
| ES (1) | ES2258173T3 (enExample) |
| MY (1) | MY129821A (enExample) |
| OA (1) | OA12667A (enExample) |
| RU (1) | RU2303349C2 (enExample) |
| WO (1) | WO2003032713A2 (enExample) |
| ZA (1) | ZA200403452B (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1976567B1 (en) | 2005-12-28 | 2020-05-13 | The Scripps Research Institute | Natural antisense and non-coding rna transcripts as drug targets |
| US8153606B2 (en) | 2008-10-03 | 2012-04-10 | Opko Curna, Llc | Treatment of apolipoprotein-A1 related diseases by inhibition of natural antisense transcript to apolipoprotein-A1 |
| CA2746003C (en) | 2008-12-04 | 2020-03-31 | Opko Curna, Llc | Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf |
| EP2370582B1 (en) | 2008-12-04 | 2017-05-10 | CuRNA, Inc. | Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene |
| CN102317458B (zh) | 2008-12-04 | 2018-01-02 | 库尔纳公司 | 通过红细胞生成素(epo)天然反义转录物的抑制对epo相关疾病的治疗 |
| PT2396038E (pt) | 2009-02-12 | 2016-02-19 | Curna Inc | Tratamento das doenças associadas com o factor neurotrófico derivado do cérebro (bdnf) por inibição do produto antisenso natural da transcrição para bdnf |
| CA2755409C (en) | 2009-03-16 | 2019-04-30 | Joseph Collard | Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2 |
| JP5904935B2 (ja) | 2009-03-17 | 2016-04-20 | クルナ・インコーポレーテッド | デルタ様１ホモログ（ｄｌｋ１）に対する天然アンチセンス転写物の抑制によるｄｌｋ１関連疾患の治療 |
| JP6250930B2 (ja) | 2009-05-06 | 2017-12-20 | クルナ・インコーポレーテッド | トリステトラプロリン（ｔｔｐ）に対する天然アンチセンス転写物の抑制によるｔｔｐ関連疾患の治療 |
| EP2427553A4 (en) | 2009-05-06 | 2012-11-07 | Opko Curna Llc | TREATMENT OF LIPID TRANSPORT AND METABOLISM-RELATED DISEASES BY INHIBITING THE NATURAL ANTISENSE TRANSCRIPT AGAINST A LIPID TRANSPORT AND METABOLIC TREATMENT |
| CN102459597B (zh) | 2009-05-08 | 2020-06-30 | 库尔纳公司 | 通过针对dmd家族的天然反义转录物的抑制治疗肌营养蛋白家族相关疾病 |
| ES2664590T3 (es) | 2009-05-18 | 2018-04-20 | Curna, Inc. | Tratamiento de enfermedades relacionadas con factores de reprogramación por inhibición del tránscrito antisentido natural a un factor de reprogramación |
| CN102549158B (zh) | 2009-05-22 | 2017-09-26 | 库尔纳公司 | 通过抑制针对转录因子e3(tfe3)的天然反义转录物来治疗tfe3和胰岛素受体底物蛋白2(irs2)相关的疾病 |
| KR101704988B1 (ko) | 2009-05-28 | 2017-02-08 | 큐알엔에이, 인크. | 항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료 |
| ES2629339T3 (es) | 2009-06-16 | 2017-08-08 | Curna, Inc. | Tratamiento de enfermedades relacionadas con la paraoxonasa 1 (pon1) por inhibición de transcrito antisentido natural a pon1 |
| CN102695797B (zh) | 2009-06-16 | 2018-05-25 | 库尔纳公司 | 通过抑制针对胶原基因的天然反义转录物来治疗胶原基因相关的疾病 |
| ES2618894T3 (es) | 2009-06-24 | 2017-06-22 | Curna, Inc. | Tratamiento de enfermedades relacionadas con el receptor del factor de necrosis tumoral 2 (tnfr2) por inhibición del transcrito natural antisentido para tnfr2 |
| KR101807324B1 (ko) | 2009-06-26 | 2017-12-08 | 큐알엔에이, 인크. | 다운 증후군 유전자에 대한 천연 안티센스 전사체의 억제에 의한 다운 증후군 유전자 관련된 질환의 치료 |
| WO2011011700A2 (en) | 2009-07-24 | 2011-01-27 | Curna, Inc. | Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
| KR101802536B1 (ko) | 2009-08-05 | 2017-11-28 | 큐알엔에이, 인크. | 인슐린 유전자 (ｉｎｓ)에 대한 자연 안티센스 전사체의 저해에 의한 인슐린 유전자 (ｉｎｓ) 관련된 질환의 치료 |
| WO2011019815A2 (en) | 2009-08-11 | 2011-02-17 | Curna, Inc. | Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq) |
| US8791087B2 (en) | 2009-08-21 | 2014-07-29 | Curna, Inc. | Treatment of ‘C terminus of HSP70-interacting protein’ (CHIP)related diseases by inhibition of natural antisense transcript to CHIP |
| CN102482671B (zh) | 2009-08-25 | 2017-12-01 | 库尔纳公司 | 通过抑制‘含有iq模体的gtp酶激活蛋白’(iqgap)的天然反义转录物而治疗iqgap相关疾病 |
| CN102791861B (zh) | 2009-09-25 | 2018-08-07 | 库尔纳公司 | 通过调节聚丝蛋白(flg)的表达和活性而治疗flg相关疾病 |
| KR101823702B1 (ko) | 2009-12-16 | 2018-01-30 | 큐알엔에이, 인크. | 막 결합 전사 인자 펩티다제, 부위 １(ｍｂｔｐｓ１)에 대한 천연 안티센스 전사체의 억제에 의한 ｍｂｔｐｓ１ 관련 질환의 치료 |
| KR101793753B1 (ko) | 2009-12-23 | 2017-11-03 | 큐알엔에이, 인크. | 커플링방지 단백질 ２(ｕｃｐ２)에 대한 천연 안티센스 전사체의 저해에 의한 ｕｃｐ２ 관련 질환의 치료 |
| DK2516648T3 (en) | 2009-12-23 | 2018-02-12 | Curna Inc | TREATMENT OF HEPATOCYTE GROWTH FACTOR (HGF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT AGAINST HGF |
| WO2011079212A2 (en) * | 2009-12-24 | 2011-06-30 | LifeSpan Extension, LLC | Methods and compositions for identifying, producing and using plant-derived products modulating cell function and aging |
| ES2657452T3 (es) | 2009-12-29 | 2018-03-05 | Curna, Inc. | Tratamiento de enfermedades relacionadas con el factor respiratorio nuclear 1 (NRF1) mediante inhibición de transcrito antisentido natural a NRF1 |
| CN102770540B (zh) | 2009-12-29 | 2017-06-23 | 库尔纳公司 | 通过抑制肿瘤蛋白63(p63)的天然反义转录物而治疗p63相关疾病 |
| RU2016115782A (ru) | 2009-12-31 | 2018-11-28 | Курна, Инк. | Лечение заболеваний, связанных с субстратом рецептора инсулина 2 (irs2), путем ингибирования природного антисмыслового транскрипта к irs2 и транскрипционному фактору е3 (tfe3) |
| DK2521784T3 (en) | 2010-01-04 | 2018-03-12 | Curna Inc | TREATMENT OF INTERFERON REGULATORY FACTOR 8- (IRF8) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPT TO IRF8 |
| WO2011085066A2 (en) | 2010-01-06 | 2011-07-14 | Curna, Inc. | Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene |
| CA2786535C (en) | 2010-01-11 | 2019-03-26 | Curna, Inc. | Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg |
| US8946182B2 (en) | 2010-01-25 | 2015-02-03 | Curna, Inc. | Treatment of RNASE H1 related diseases by inhibition of natural antisense transcript to RNASE H1 |
| JP5976548B2 (ja) | 2010-02-22 | 2016-08-23 | カッパーアールエヌエー，インコーポレイテッド | Ｐｙｃｒ１に対する天然アンチセンス転写物の阻害によるピロリン−５−カルボン酸レダクターゼ１（ｐｙｃｒ１）関連疾患の治療 |
| TWI600759B (zh) | 2010-04-02 | 2017-10-01 | 可娜公司 | 藉由抑制群落刺激因子３（ｃｓｆ３）之天然反義轉錄物以治療ｃｓｆ３相關疾病 |
| US9044494B2 (en) | 2010-04-09 | 2015-06-02 | Curna, Inc. | Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21 |
| US9089588B2 (en) | 2010-05-03 | 2015-07-28 | Curna, Inc. | Treatment of sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a sirtuin (SIRT) |
| TWI531370B (zh) | 2010-05-14 | 2016-05-01 | 可娜公司 | 藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病 |
| EP3299464B1 (en) | 2010-05-26 | 2019-10-02 | CuRNA, Inc. | Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1 |
| EP2576784B1 (en) | 2010-05-26 | 2017-11-15 | CuRNA, Inc. | Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra |
| JP6023705B2 (ja) | 2010-06-23 | 2016-11-09 | カッパーアールエヌエー，インコーポレイテッド | ナトリウムチャネル、電位依存性、αサブユニット（ＳＣＮＡ）に対する天然アンチセンス転写物の阻害によるＳＣＮＡ関連疾患の治療 |
| CN103068982B (zh) | 2010-07-14 | 2017-06-09 | 库尔纳公司 | 通过抑制盘状大同系物(dlg)的天然反义转录物而治疗dlg相关疾病 |
| US8993533B2 (en) | 2010-10-06 | 2015-03-31 | Curna, Inc. | Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4 |
| WO2012054723A2 (en) | 2010-10-22 | 2012-04-26 | Opko Curna Llc | Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua |
| WO2012068340A2 (en) | 2010-11-18 | 2012-05-24 | Opko Curna Llc | Antagonat compositions and methods of use |
| EP2643463B1 (en) | 2010-11-23 | 2017-09-27 | CuRNA, Inc. | Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog |
| EP2718439B1 (en) | 2011-06-09 | 2017-08-09 | CuRNA, Inc. | Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn |
| EP2753317B1 (en) | 2011-09-06 | 2020-02-26 | CuRNA, Inc. | TREATMENT OF DISEASES RELATED TO ALPHA SUBUNITS OF SODIUM CHANNELS, VOLTAGE-GATED (SCNxA) WITH SMALL MOLECULES |
| HK1210211A1 (en) | 2012-03-15 | 2016-04-15 | 科纳公司 | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
| CN102643800B (zh) * | 2012-04-25 | 2014-02-05 | 中国科学院植物研究所 | 一种提取植物dna的方法及其专用试剂盒 |
| GB201708665D0 (en) * | 2017-05-31 | 2017-07-12 | Tropic Biosciences Uk Ltd | Compositions and methods for increasing extractability of solids from coffee beans |
| IL313387A (en) | 2017-09-19 | 2024-08-01 | Tropic Biosciences Uk Ltd | Modifying the specificity of non-coding rna molecules for silencing gene expression in eukaryotic cells |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6329191B1 (en) * | 1993-08-30 | 2001-12-11 | Hawaii Biotechnology Group, Inc. | DNA encoding recombinant coffee bean alpha-galactosidase |
| EP1138771A1 (fr) * | 2000-03-30 | 2001-10-04 | Societe Des Produits Nestle S.A. | Endo-Mannanase de café |
-
2002
- 2002-08-15 EP EP02801285A patent/EP1436402B1/en not_active Expired - Lifetime
- 2002-08-15 JP JP2003535528A patent/JP4276945B2/ja not_active Expired - Fee Related
- 2002-08-15 WO PCT/EP2002/009148 patent/WO2003032713A2/en not_active Ceased
- 2002-08-15 DE DE60209380T patent/DE60209380T2/de not_active Expired - Lifetime
- 2002-08-15 ES ES02801285T patent/ES2258173T3/es not_active Expired - Lifetime
- 2002-08-15 BR BR0213180-3A patent/BR0213180A/pt not_active IP Right Cessation
- 2002-08-15 AT AT02801285T patent/ATE318319T1/de not_active IP Right Cessation
- 2002-08-15 RU RU2004114230/13A patent/RU2303349C2/ru not_active IP Right Cessation
- 2002-08-15 CN CNA028200861A patent/CN1635895A/zh active Pending
- 2002-08-15 OA OA1200400102A patent/OA12667A/en unknown
- 2002-08-15 CA CA002457821A patent/CA2457821A1/en not_active Abandoned
- 2002-08-15 AU AU2002333434A patent/AU2002333434B2/en not_active Ceased
- 2002-08-26 MY MYPI20023142A patent/MY129821A/en unknown
-
2004
- 2004-03-19 US US10/804,096 patent/US7238858B2/en not_active Expired - Lifetime
- 2004-04-05 CO CO04032188A patent/CO5580845A2/es not_active Application Discontinuation
- 2004-05-06 ZA ZA200403452A patent/ZA200403452B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE318319T1 (de) | 2006-03-15 |
| ZA200403452B (en) | 2006-07-26 |
| WO2003032713A3 (en) | 2003-11-13 |
| DE60209380D1 (de) | 2006-04-27 |
| RU2303349C2 (ru) | 2007-07-27 |
| CN1635895A (zh) | 2005-07-06 |
| AU2002333434B2 (en) | 2007-12-13 |
| BR0213180A (pt) | 2004-09-14 |
| OA12667A (en) | 2006-06-19 |
| US20040199943A1 (en) | 2004-10-07 |
| US7238858B2 (en) | 2007-07-03 |
| WO2003032713A2 (en) | 2003-04-24 |
| EP1436402A2 (en) | 2004-07-14 |
| CO5580845A2 (es) | 2005-11-30 |
| RU2004114230A (ru) | 2005-04-20 |
| MY129821A (en) | 2007-05-31 |
| CA2457821A1 (en) | 2003-04-24 |
| EP1436402B1 (en) | 2006-02-22 |
| DE60209380T2 (de) | 2006-10-19 |
| JP2005505290A (ja) | 2005-02-24 |
| ES2258173T3 (es) | 2006-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4276945B2 (ja) | α−Ｄ−ガラクトシダーゼ活性が低下したコーヒー植物 | |
| AU2002333434A1 (en) | Coffee plant with reduced alpha-D-galactosidase activity | |
| US6235482B1 (en) | Strawberry promoters and genes | |
| ES2602133T3 (es) | Reproducción precisa | |
| US20050009165A1 (en) | Raffinose synthase gene, method for producing raffinose, and transgenic plant | |
| US6160204A (en) | Polyphenol oxidase cDNA | |
| TW201720929A (zh) | 馬鈴薯栽培品種y9 | |
| JPH08510645A (ja) | 貯蔵ジャガイモの品質を改良する方法 | |
| AU697450B2 (en) | Processes for inhibiting and for inducing flower formation in plants | |
| EP1081223A1 (en) | Promoter sequences expressed in anthers and pollens | |
| US5569831A (en) | Transgenic tomato plants with altered polygalacturonase isoforms | |
| EP0994186A1 (en) | Raffinose synthetase gene, process for producing raffinose, and transformed plant | |
| CN116656698B (zh) | 玉米基因Zm00001d018037在提高单子叶农作物抗旱性能方面的应用 | |
| JPH10512451A (ja) | グルタチオンｓ−トランスフェラーゼをコードするデオキシリボ核酸およびその使用 | |
| US7250277B2 (en) | Soybean raffinose synthase and a method for producing raffinose | |
| CN119930772B (zh) | 一种水稻基因在调控磷素稳态的应用 | |
| JP2004016201A (ja) | 花芽形成抑制遺伝子及び早期開花性が付与された植物 | |
| CN119684420B (zh) | 一种增强高粱碱耐受性的基因SbAIF1及其应用 | |
| KR20050018626A (ko) | 감소된 α-Ｄ-갈락토시다아제 활성을 갖는 커피 식물 | |
| RU2145636C1 (ru) | Способ индуцирования образования цветков у растений | |
| ES2292639T3 (es) | Acidos nucleicos que codifican las invertasas vacuolares, las celulas vegetales y las plantas que contienen dichos acidos nucleicos, y el uso de los mismos. | |
| JP3030015B2 (ja) | エチレン低感受性植物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050707 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20061110 |
|
| RD05 | Notification of revocation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7425 Effective date: 20070314 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080715 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081014 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081021 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081117 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081125 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081215 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081222 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20090115 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20090115 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090303 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090309 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4276945 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120313 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120313 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130313 Year of fee payment: 4 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130313 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140313 Year of fee payment: 5 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |